Gesellschaft Zur Forderung Des Wissenschaftlich Medizinischen Erkenntnisgewinns In Der Hamatologie Und Oncologie
- Address
- lock Available on a paid plan
Gesellschaft Zur Forderung Des Wissenschaftlich Medizinischen Erkenntnisgewinns In Der Hamatologie Und Oncologie
This German oncology research society specializes in advancing clinical knowledge across hematological malignancies and solid tumors. The center demonstrates extensive expertise in gastrointestinal cancers, particularly colorectal, esophageal, and rectal cancers, while maintaining strong programs in lung cancer and lymphoid malignancies. Their research portfolio encompasses innovative approaches including immunotherapy combinations, targeted therapies, and precision medicine strategies guided by biomarkers such as ctDNA and molecular profiling.
- Colorectal cancer across all stages: organ-preserving approaches, perioperative chemotherapy strategies, and ctDNA-guided adjuvant therapy in stage II disease
- Non-small cell lung cancer: adjuvant immunotherapy combinations, personalized cancer vaccines, and targeted therapies for EGFR-mutated and MET-altered disease
- Lymphoid malignancies: novel immunotherapies for marginal zone lymphoma, follicular lymphoma, Waldenström's macroglobulinemia, and chronic lymphocytic leukemia
- Myelodysplastic syndromes: first-line treatment strategies to prevent transfusion dependence in lower-risk patients
The center conducts comprehensive Phase II and Phase III clinical trials evaluating cutting-edge therapeutic combinations including checkpoint inhibitors, BTK inhibitors, BCL-2 inhibitors, and antibody-drug conjugates. Their research emphasizes both improving survival outcomes and reducing treatment-related morbidity through organ preservation strategies, particularly in esophageal and rectal cancers. The organization collaborates extensively with international networks including the AIO (Arbeitsgemeinschaft Internistische Onkologie) and FLOT study groups to advance evidence-based treatment paradigms in hematology and oncology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 56 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1AstraZeneca AB2active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gesellschaft Zur Forderung Des Wissenschaftlich Medizinischen Erkenntnisgewinns In Der Hamatologie Und Oncologie
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17 | University Of Cologne | Phase III | Not Recruiting | Feb 2021 | — |
IMP list
lock Showing 1 of 56 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 5 | Unknown | 2023-03-28 | 2026-06-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.